Literature DB >> 20062086

Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.

S Murayama-Hosokawa1, K Oda, S Nakagawa, S Ishikawa, S Yamamoto, K Shoji, Y Ikeda, Y Uehara, M Fukayama, F McCormick, T Yano, Y Taketani, H Aburatani.   

Abstract

Endometrial cancer is one of the tumor types in which either chromosomal instability (CIN) or microsatellite instability (MSI) may occur. It is known to possess mutations frequently in the Ras-PI3K (phosphatidylinositol 3'-kinase) pathway. We performed a comprehensive genomic survey in 31 endometrial carcinomas with paired DNA for chromosomal imbalances (25 by the 50K and 6 by the 250K single-nucleotide polymorphism (SNP) array), and screened 25 of the 31 samples for MSI status and mutational status in the Ras-PI3K pathway genes. We detected five or more copy number changes (classified as CIN-extensive) in 9 (29%), 1 to 4 changes (CIN-intermediate) in 17 (55%) and no changes (CIN-negative) in 5 (16%) tumors. Positive MSI was less common in CIN-extensive tumors (14%), compared with CIN-intermediate/negative tumors (50%), and multivariate analysis showed that CIN-extensive is an independent poor prognostic factor. SNP array analysis unveiled copy number neutral LOH at 54 loci in 13 tumors (42%), including four at the locus of PTEN. In addition to eight (26%) tumors with PTEN deletions, we detected chromosomal imbalances of NF1, K-Ras and PIK3CA in four (13%), four (13%) and six (19%) tumors, respectively. In all, 7 of the 9 CIN-extensive tumors harbor deletions in the loci of PTEN and/or NF1, whereas all the 10 MSI-positive tumors possess PTEN, PIK3CA and/or K-Ras mutations. Our results showed that genomic alterations in the Ras-PI3K pathway are remarkably widespread in endometrial carcinomas, regardless of the type of genomic instability, and suggest that the degree of CIN is a useful biomarker for prognosis in endometrial carcinomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20062086     DOI: 10.1038/onc.2009.474

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors:  Li-E Wang; Hongxia Ma; Katherine S Hale; Ming Yin; Larissa A Meyer; Hongliang Liu; Jie Li; Karen H Lu; Bryan T Hennessy; Xuesong Li; Margaret R Spitz; Qingyi Wei; Gordon B Mills
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-07       Impact factor: 4.553

Review 2.  Cancer chromosomal instability: therapeutic and diagnostic challenges.

Authors:  Nicholas McGranahan; Rebecca A Burrell; David Endesfelder; Marco R Novelli; Charles Swanton
Journal:  EMBO Rep       Date:  2012-06-01       Impact factor: 8.807

3.  A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma.

Authors:  Yunyun Li; Zhongzu Zhang; Xiaojing Zhang; Ying Lin; Tangshu Luo; Zhenghua Xiao; Qin Zhou
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.

Authors:  Meghan L Rudd; Jessica C Price; Sarah Fogoros; Andrew K Godwin; Dennis C Sgroi; Maria J Merino; Daphne W Bell
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

5.  Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.

Authors:  Linghua Wang; Shuichi Tsutsumi; Tokuichi Kawaguchi; Koichi Nagasaki; Kenji Tatsuno; Shogo Yamamoto; Fei Sang; Kohtaro Sonoda; Minoru Sugawara; Akio Saiura; Seiko Hirono; Hiroki Yamaue; Yoshio Miki; Minoru Isomura; Yasushi Totoki; Genta Nagae; Takayuki Isagawa; Hiroki Ueda; Satsuki Murayama-Hosokawa; Tatsuhiro Shibata; Hiromi Sakamoto; Yae Kanai; Atsushi Kaneda; Tetsuo Noda; Hiroyuki Aburatani
Journal:  Genome Res       Date:  2011-12-07       Impact factor: 9.043

6.  Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Authors:  Keiko Shoji; Katsutoshi Oda; Tomoko Kashiyama; Yuji Ikeda; Shunsuke Nakagawa; Kenbun Sone; Yuichiro Miyamoto; Haruko Hiraike; Michihiro Tanikawa; Aki Miyasaka; Takahiro Koso; Yoko Matsumoto; Osamu Wada-Hiraike; Kei Kawana; Hiroyuki Kuramoto; Frank McCormick; Hiroyuki Aburatani; Tetsu Yano; Shiro Kozuma; Yuji Taketani
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

7.  Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors.

Authors:  Nelson Lourenço; Zofia Hélias-Rodzewicz; Jean-Baptiste Bachet; Sabrina Brahimi-Adouane; Fabrice Jardin; Jeanne Tran van Nhieu; Frédérique Peschaud; Emmanuel Martin; Alain Beauchet; Frédéric Chibon; Jean-François Emile
Journal:  Mol Cancer       Date:  2014-11-06       Impact factor: 27.401

8.  Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.

Authors:  Yuriko Uehara; Katsutoshi Oda; Yuji Ikeda; Takahiro Koso; Shingo Tsuji; Shogo Yamamoto; Kayo Asada; Kenbun Sone; Reiko Kurikawa; Chinami Makii; Otoe Hagiwara; Michihiro Tanikawa; Daichi Maeda; Kosei Hasegawa; Shunsuke Nakagawa; Osamu Wada-Hiraike; Kei Kawana; Masashi Fukayama; Keiichi Fujiwara; Tetsu Yano; Yutaka Osuga; Tomoyuki Fujii; Hiroyuki Aburatani
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

9.  Synthetic genetic targeting of genome instability in cancer.

Authors:  Babu V Sajesh; Brent J Guppy; Kirk J McManus
Journal:  Cancers (Basel)       Date:  2013-06-24       Impact factor: 6.639

10.  Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.

Authors:  Yuji Ikeda; Katsutoshi Oda; Hideki Ishihara; Osamu Wada-Hiraike; Aki Miyasaka; Tomoko Kashiyama; Kanako Inaba; Tomohiko Fukuda; Kenbun Sone; Yoko Matsumoto; Takahide Arimoto; Daichi Maeda; Masako Ikemura; Masahi Fukayama; Kei Kawana; Tetsu Yano; Daisuke Aoki; Yutaka Osuga; Tomoyuki Fujii
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.